NEOG Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of -4.96% compared to Neogen's net margin of 14.45%. Neogen's return on equity of -16.44% beat Boston Scientific's return on equity of 9.57%.

Neogen has a consensus price target of $9.00, signalling upside risk potential of 57.76%. On the other hand Boston Scientific has an analysts' consensus of $117.02 which suggests that it could grow by 18.73%. Given that Neogen has higher upside potential than Boston Scientific, analysts believe Neogen is more attractive than Boston Scientific.

Neogen has a beta of 1.841, which suggesting that the stock is 84.136% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.681, suggesting its less volatile than the S&P 500 by 31.908%.

Neogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Neogen quarterly revenues are $221M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Neogen's net income of -$11M is lower than Boston Scientific's net income of $674M. Notably, Neogen's price-to-earnings ratio is 2,124.15x while Boston Scientific's PE ratio is 71.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen is 1.37x versus 8.36x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of -4.96% compared to Neogen's net margin of 30.99%. Neogen's return on equity of -16.44% beat Intuitive Surgical's return on equity of 15.82%.

Neogen has a consensus price target of $9.00, signalling upside risk potential of 57.76%. On the other hand Intuitive Surgical has an analysts' consensus of $575.49 which suggests that it could grow by 12.18%. Given that Neogen has higher upside potential than Intuitive Surgical, analysts believe Neogen is more attractive than Intuitive Surgical.

Neogen has a beta of 1.841, which suggesting that the stock is 84.136% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.875%.

Neogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Neogen quarterly revenues are $221M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Neogen's net income of -$11M is lower than Intuitive Surgical's net income of $698.4M. Notably, Neogen's price-to-earnings ratio is 2,124.15x while Intuitive Surgical's PE ratio is 75.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen is 1.37x versus 21.37x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Microbot Medical has a net margin of -4.96% compared to Neogen's net margin of --. Neogen's return on equity of -16.44% beat Microbot Medical's return on equity of --.

Neogen has a consensus price target of $9.00, signalling upside risk potential of 57.76%. On the other hand Microbot Medical has an analysts' consensus of $9.00 which suggests that it could grow by 262.9%. Given that Microbot Medical has higher upside potential than Neogen, analysts believe Microbot Medical is more attractive than Neogen.

Neogen has a beta of 1.841, which suggesting that the stock is 84.136% more volatile than S&P 500. In comparison Microbot Medical has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.762%.

Neogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Microbot Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen pays -- of its earnings as a dividend. Microbot Medical pays out -- of its earnings as a dividend.

Neogen quarterly revenues are $221M, which are larger than Microbot Medical quarterly revenues of --. Neogen's net income of -$11M is lower than Microbot Medical's net income of -$2.6M. Notably, Neogen's price-to-earnings ratio is 2,124.15x while Microbot Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen is 1.37x versus -- for Microbot Medical. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of -4.96% compared to Neogen's net margin of 11.15%. Neogen's return on equity of -16.44% beat Stryker's return on equity of 14.2%.

Neogen has a consensus price target of $9.00, signalling upside risk potential of 57.76%. On the other hand Stryker has an analysts' consensus of $421.46 which suggests that it could grow by 10.6%. Given that Neogen has higher upside potential than Stryker, analysts believe Neogen is more attractive than Stryker.

Neogen has a beta of 1.841, which suggesting that the stock is 84.136% more volatile than S&P 500. In comparison Stryker has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.615%.

Neogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.86% to investors and pays a quarterly dividend of $0.84 per share. Neogen pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neogen quarterly revenues are $221M, which are smaller than Stryker quarterly revenues of $5.9B. Neogen's net income of -$11M is lower than Stryker's net income of $654M. Notably, Neogen's price-to-earnings ratio is 2,124.15x while Stryker's PE ratio is 51.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen is 1.37x versus 6.33x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.